NEW YORK, April 6 (GenomeWeb News) - Genaissance Pharmaceuticals said today that it has signed agreements with the University of Rochester and the Mayo Clinic for access to clinical research samples, associated data, and intellectual property around certain disease-associated mutations that it will use in developing genetic tests for cardiac disease.
Genaissance said it expects to launch the first such test, for cardiac ion channel mutations, in May. The test will include mutations responsible for Familial Long QT and Brugada Syndromes, and will be conducted in the company's CLIA-licensed laboratory in New Haven, Conn.
"It is our intention to build a pharmacogenomic franchise around the genetics of cardiac ion channel mutations," said Richard Judson, senior vice president and CSO of Genaissance, in a statement.
As part of the agreements, Michael Ackerman, associate professor at the Mayo Clinic College of Medicine and director of the Long QT Syndrome Clinic, and Arthur Moss, professor of medicine at the University of Rochester, will serve on Genaissance's advisory board.